New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. Gradishar

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. GradisharПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Irene and Dr. VogelПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Traina & Dr. CareyПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Kaklamani and Dr. O’ReganПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

Dr. Pegram on Neoadjuvant Treatments for HER2-Postive Breast CancerПодробнее

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее

Optimizing Therapy for HER2-Positive Breast Cancer Study (CompassHER2-pCR)Подробнее

Optimizing Therapy in HER2+ Disease with Dr. Kevin KalinskyПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Meisel & Dr. SolimanПодробнее

Treatment Updated for HER2 Positive Breast Cancer: Changing ParadigmsПодробнее

Considerations for Pre-operative Therapy to Optimize Care of Women with HER2+ Breast CancerПодробнее

What is HER2 Testing in Breast Cancer? | Dr Kiley LohПодробнее

Treatment optimization trials in breast cancerПодробнее

Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine ResistanceПодробнее

Contrast enhanced mammography workflow and economics in breast cancer institutesПодробнее

Dr. Hortobagyi on MONALEESA-2 Trial Results in Breast CancerПодробнее

Results of the MONALEESA-2 Study in Advanced Breast CancerПодробнее

Dr. Tripathy Discusses Immunotherapy in HER2+ Breast CancerПодробнее